Mereo BioPharma Group Plc
(NASDAQ : MREO)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc. -0.35%62.981.0%$472.19m
AMGNAmgen, Inc. 0.41%241.491.3%$448.51m
BIIBBiogen, Inc. -0.22%285.501.4%$387.69m
ILMNIllumina, Inc. -0.38%324.723.5%$323.34m
VRTXVertex Pharmaceuticals, Inc. 0.14%235.831.9%$300.14m
REGNRegeneron Pharmaceuticals, Inc. 0.10%385.942.6%$230.50m
EXASEXACT Sciences Corp. -1.92%88.0624.0%$205.44m
ALXNAlexion Pharmaceuticals, Inc. 0.68%113.272.0%$195.57m
ITCIIntra-Cellular Therapies, Inc. -1.43%26.259.0%$173.00m
INCYIncyte Corp. -0.15%80.502.5%$148.96m
SRPTSarepta Therapeutics, Inc. -1.84%127.9014.6%$138.72m
ARWRArrowhead Pharmaceuticals, Inc. -1.21%56.4211.3%$132.45m
SGENSeattle Genetics, Inc. 1.25%109.006.1%$122.98m
AAgilent Technologies, Inc. 0.79%90.171.6%$113.52m
BMRNBioMarin Pharmaceutical, Inc. -0.97%88.274.3%$108.30m

Company Profile

Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.